• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, October 10, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Drs. Dawn Hershman and Primo Lara elected group co-chairs-elect of SWOG Cancer Research Network

Bioengineer by Bioengineer
May 16, 2023
in Health
Reading Time: 2 mins read
0
SWOG Group Co-Chairs-Elect
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The board of governors of the SWOG Cancer Research Network has elected Primo N. Lara, Jr., MD, and Dawn L. Hershman, MD, MS, as group co-chairs-elect. The two will serve in that capacity until the term of the current group chair, Charles D. Blanke, MD, ends in spring 2025. They will then begin a six-year term as SWOG’s first group co-chairs.

SWOG Group Co-Chairs-Elect

Credit: Courtesy UC Davis Comprehensive Cancer Center & Columbia University/Herbert Irving Comprehensive Cancer Center

The board of governors of the SWOG Cancer Research Network has elected Primo N. Lara, Jr., MD, and Dawn L. Hershman, MD, MS, as group co-chairs-elect. The two will serve in that capacity until the term of the current group chair, Charles D. Blanke, MD, ends in spring 2025. They will then begin a six-year term as SWOG’s first group co-chairs.

In a joint statement, Hershman and Lara said, “We both understand that the success of SWOG has been fundamentally anchored in collaborative interdisciplinary team science. We are convinced that a multi-PI approach at the group chair level truly represents SWOG’s highly successful team-based nature.”

“We believe that the breadth and depth of our experiences and skillsets in clinical and translational cancer research within SWOG and across the NCTN and NCORP are so highly complementary and synergistic that we expect nothing more than even greater impact of SWOG’s activities into the foreseeable future.”

Hershman is an American Cancer Society Professor of Medicine and Epidemiology and interim chief of the Division of Hematology/Oncology at Columbia University Irving Medical Center. She is also deputy director of the Herbert Irving Comprehensive Cancer Center. Within SWOG, she serves as SWOG’s vice chair for NCI Community Oncology Research Program (NCORP) research.

Lara is professor of medicine and executive associate dean for cancer programs at the University of California Davis School of Medicine. He is also director of the NCI-designated UC Davis Comprehensive Cancer Center, and within SWOG he serves as the group’s deputy chair and vice chair of operations. 
 

SWOG Cancer Research Network is part of the National Cancer Institute’s National Clinical Trials Network and the NCI Community Oncology Research Program and is part of the oldest and largest publicly funded cancer research network in the nation. SWOG has more than 18,000 members in 45 states and nine foreign countries who design and conduct clinical trials to improve the lives of people with cancer. SWOG trials have led to the approval of 14 cancer 



Share12Tweet8Share2ShareShareShare2

Related Posts

Gene Expression Scores Predict Aging Outcomes

October 10, 2025

Tackling Inappropriate Prescribing Cascades for Safer Meds

October 10, 2025

New Inhibitor 4′-O-methylochnaflavone Targets HSP90AB1 in Cancer

October 10, 2025

Women Receive ADHD Diagnoses Five Years Later Than Men, Though Symptoms Emerge Simultaneously

October 10, 2025

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1201 shares
    Share 480 Tweet 300
  • New Study Reveals the Science Behind Exercise and Weight Loss

    102 shares
    Share 41 Tweet 26
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    96 shares
    Share 38 Tweet 24
  • Revolutionizing Optimization: Deep Learning for Complex Systems

    84 shares
    Share 34 Tweet 21

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Gene Expression Scores Predict Aging Outcomes

Tackling Inappropriate Prescribing Cascades for Safer Meds

New Inhibitor 4′-O-methylochnaflavone Targets HSP90AB1 in Cancer

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 63 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.